Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph(+) ALL) cases and immunotherapeutic approaches, including...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Moujalled, Donia M., Hanna, Diane T., Hediyeh-zadeh, Soroor, Pomilio, Giovanna, Brown, Lauren, Litalien, Veronique, Bartolo, Ray, Fleming, Shaun, Chanrion, Maïa, Banquet, Sébastien, Maragno, Ana-Leticia, Kraus-Berthier, Laurence, Schoumacher, Marie, Mullighan, Charles G., Georgiou, Angela, White, Christine A., Lessene, Guillaume, Huang, David C. S., Roberts, Andrew W., Geneste, Olivier, Rasmussen, Lorna, Davis, Melissa J., Ekert, Paul G., Wei, Andrew, Ng, Ashley P., Khaw, Seong L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322969/
https://ncbi.nlm.nih.gov/pubmed/32569380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001416
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados